Biophytis SA Sustainability Reports
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging. Its lead drug candidate, BIO101, is being developed to treat muscular diseases such as sarcopenia and age-related respiratory failure.
Sector: Professional & technical services
Country: France
Exchange: Euronext Paris
LEI: 9695008GIE061NBGU106
FIGI: BBG003G0SFR2
7 reports from 2016 to 2025
